Exploring the MicroRNA Landscape in Cardiac Amyloidosis: Molecular Insights and Clinical Applications
Authors:
- Joanna E. KontarakiJKJoanna E. Kontaraki
- Anthoula PlevritakiAnthoula Plevritaki
- Aleksi SalloASAleksi Sallo
- Konstantinos FragkiadakisKFKonstantinos Fragkiadakis
- Eleutherios KallergisEKEleutherios Kallergis
- Evangelos ZacharisEZEvangelos Zacharis
- John KopidakisJKJohn Kopidakis
- Emmanouil KampanierisEKEmmanouil Kampanieris
- Sophia AchladianakiSASophia Achladianaki
- Vasiliki PapakostaVPVasiliki Papakosta
- Emmanouil SimantirakisESEmmanouil Simantirakis
- Maria E. MarketouMaria E. Marketou
Open Access
Abstract
Background: Cardiac amyloidosis (CA) is an increasingly recognized cause of heart failure with preserved ejection fraction, resulting from myocardial deposition of misfolded amyloid fibrils derived predominantly from transthyretin (ATTR wild-type [ATTRwt] or variant [ATTRv]) or immunoglobulin light chains (AL). Despite advances in noninvasive imaging and disease-modifying therapies, delayed diagnosis remains common, and clinically actionable molecular biomarkers for early detection, phenotypic discrimination, and therapeutic monitoring are limited. MicroRNAs (miRNAs), small noncoding regulators of post-transcriptional gene expression, have emerged as key modulators of cardiovascular remodeling and systemic amyloid biology. Methods: We performed a comprehensive review of experimental, translational, and clinical studies to evaluate the role of miRNAs in transthyretin and light-chain cardiac amyloidosis, incorporating data from myocardial tissue analyses, circulating miRNA profiling, and mechanistic studies in cellular and animal models. Results: Dysregulated miRNA networks contribute to amyloid-induced cardiac injury by modulating mitochondrial energetics, oxidative stress, inflammation, fibrosis, proteostasis, and neurocardiac signaling. Specific miRNAs, including members of the miR-21, miR-29, and miR-30 families, as well as miR-150-5p and miR-339, have been associated with amyloid burden, adverse myocardial remodeling, plasma cell biology, and disease severity. Distinct circulating and tissue miRNA signatures differentiate transthyretin from light-chain cardiac amyloidosis and correlate with functional status, heart failure biomarkers, and clinical outcomes. Conclusions: MiRNAs represent promising diagnostic and prognostic biomarkers in cardiac amyloidosis and offer mechanistic insights into disease pathogenesis. Integration of miRNA profiling with multimodality imaging and emerging RNA-based therapeutics may enable earlier diagnosis and support precision management of amyloid-related heart failure.Keywords
All Related Versions
This publication has 94 references indexed in Scilit:
- Targeting mitochondrial microRNAs in cardiovascular pathologies: A new frontier in precision cardiologyAgeing Research Reviews, 2025
- Arrhythmien bei AmyloidoseHerzschrittmachertherapie + Elektrophysiologie, 2024
- MicroRNAs are Associated with Cardiac Biomarkers, Cardiac Structure and Function and Incident Outcomes in Heart FailureESC Heart Failure, 2024
- Atrial amyloidosis: mechanisms and clinical manifestationsEuropean Journal of Heart Failure, 2022
- Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internistInternal and Emergency Medicine, 2022
- Identification of Novel Circulating microRNAs in Advanced Heart Failure by Next-Generation SequencingESC Heart Failure, 2021
- Use of biomarkers to diagnose and manage cardiac amyloidosisEuropean Journal of Heart Failure, 2021
- Inhibition of miR‐181b‐5p protects cardiomyocytes against ischemia/reperfusion injury by targeting AKT3 and PI3KR3Journal of Cellular Biochemistry, 2019
- Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac AmyloidosisJAMA, 2017
- Mitochondrial-Shaping Proteins in Cardiac Health and Disease – the Long and the Short of It!Cardiovascular Drugs and Therapy, 2017